7.18 USD
0.000.00%
盘后 7.16 -0.28%
2026-08-03
市值
$2.66B
市盈率
—
EPS
-2.44
股息率
—
52 周区间
3.27 – 7.22
成交量
6.32M
Beta
1.55
目标价
9.59
52W 低 3.2752W 高 7.22
价格走势
公司简介
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophr...